Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GDA 201

Next Previous
X
Search
Drug Profile

GDA 201

Alternative Names: Allogeneic GDA 201 NK cells; GDA-201; NAM NK cells - Gamida; NAM-NK Cells; Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells

Latest Information Update: 17 May 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Gamida-Cell
  • Developer Gamida-Cell; University of Minnesota
  • Class Antineoplastics; Cell therapies; Immunotherapies; Natural killer cell therapies
  • Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Non-Hodgkin's lymphoma
  • No development reported Multiple myeloma; Solid tumours

Most Recent Events

  • 22 Apr 2024 Gamida terminates a phase I/II trial in Non-Hodgkin's lymphoma (Combination therapy, Second-line therapy or greater) in USA (IV), due to sponsor decision (NCT05296525)
  • 23 Feb 2024 Efficacy data from a phase I/II trial in Non-Hodgkin's lymphoma released by Gamida Cell
  • 16 Oct 2023 Efficacy and adverse events data form phase I/II clinical trials in Non-Hodgkin's lymphoma released by Gamida Cell

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top